The testosterone-support market is a $4.5 billion opportunity, growing 10% annually, with new brands reaching $100 million scale in under two years. Even the U.S. Pentagon has brought testosterone screening into the spotlight. But as demand accelerates, a testosterone gap is emerging between market growth and credible science. Using Tongkat Ali as a case study, experts will examine why 100:1, 200:1 and 300:1 extract ratios can mislead, and how standardization and clinical evidence reveal what drives efficacy. Not all extracts are created equal. The winners will be brands that can prove their products work, not just claim they do.
Speakers:
- Chris Kilham, Ethnobotanist, Author & Medicine Hunter
- Dr. Annie George, Head of R&D, Biotropics Malaysia
- Joel Neoh, Director, Biotropics Malaysia
- Stefan Gafner, Chief Scientific Officer, American Botanical Council